52-104 Week Off-therapy Second Extension to Study CSPP100A2365

Noden Pharma

Status: Completed

Conditions: Hypertension

Treatments: Drug: SPP100

Study type: Observational

Funder types: Industry

Identifiers

NCT01420068

CSPP100A2365E2

2011-004411-22

Details and patient eligibility

About

52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1

Enrollment: 106 patients

Sex: All

Ages: 6 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Successful completion of study CSPP100A2365E1
• Patients must meet inclusion criteria set forth for trials CSPP100A2365 and CSPP100A2365E1
• Informed consent/ patient assent

Exclusion criteria

•Patients who did not successfully complete studies CSPP100A2365 and CSPP100A2365E1

Trial design

106 participants in 1 patient group

All patients

Description:

All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.

Treatment:

Drug: SPP100